LungLife AI, with Collaborators from Mount Sinai and MD Anderson, to Present Clinical Data on Liquid Biopsy Test for Early Lung Cancer Detection

THOUSAND OAKS, CA – October 1, 2020 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that clinical data from a research collaboration in early lung cancer detection will be presented at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting taking place on October 2nd and 3rd. The data highlight the Company’s progress in developing the LungLB® test which discriminates benign from malignant lesions in individuals with indeterminate lung nodules who are at risk for lung cancer.

The study is being completed with collaborators from Mount Sinai Hospital in New York and MD Anderson Cancer Center in Houston, and demonstrates the potential of circulating tumor cells (CTC) for early lung cancer detection. LungLife AI is also presenting on the use of artificial intelligence in accurate CTC identification developed in partnership with Persistent Systems.

“Lung cancer spreads early and by using CTCs we are best positioned to find malignancy at the earliest possible stage,” says Paul Pagano, PhD, CEO at LungLife AI. “The majority of cancerous nodules in our study were diagnosed at Stage I, when the possibility for cure is greatest. We are delighted to have the opportunity to share results of our pilot study with scientists, physicians, and advocates.”

The following are the details for the two presentations:

Title:  Pilot study of a novel liquid biopsy test to discriminate benign vs malignant processes in subjects with indeterminate pulmonary nodules
Abstract Number: 034
Type: Oral Poster Presentation
Presenters: Joshua D Kuban1, Shahram Tahvilian2, Lara Baden2, Claudia I Henschke3, David F Yankelevitz3, Daniel Leventon2, Rebecca Reed2, Ashley Brown2, Allison Muldoon2, Michael J Donovan4, Paul C Pagano2

1.     Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX

2.     LungLife AI, Inc, Thousand Oaks, CA

3.     Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY

4.     Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 

Title:  Use of an artificial intelligence-derived algorithm for accurate FISH probe detection in a liquid biopsy test for lung cancer

Abstract Number:   039
Type: Poster Presentation
Presenters: Shahram Tahvilian1, Chinmay Savadikar2, Lara Baden1, Daniel Leventon1, Rebecca Reed1, Ashley Brown1, Michael J Donovan3, Bhushan Garware2, Paul C Pagano1

1.     LungLife AI, Inc, Thousand Oaks, CA

2.     Persistent Systems, Ltd, Pune, India

3.     Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY. 

About LungLife AI, Inc.

LungLife AI is a cancer diagnostics company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled molecular analysis of cancer biomarkers in blood.

LungLife AI is focused upon lung cancer diagnostic solutions recognizing the need to substantially improve patient outcomes. The company's testing methodology is designed to deliver actionable information to clinicians via a minimally invasive blood draw.

LungLife AI is based in Thousand Oaks, California. For more information, please visit https://www.lunglifeAI.com/.

LungLife AI Receives CLIA certification for its Cancer Diagnostic Laboratory

LungLife AI, the developer of an Artificial Intelligence (AI) enabled non-invasive liquid biopsy test for the early detection of lung cancer, announced today that the Company has received certification from the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the US Department of Health and Human Services (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license.

“Today’s CLIA certification marks a pivotal step towards the commercialization of leading cancer diagnostics for early-stage lung cancer. Our LungLB® test will provide a significant impact on patient outcomes and to clinical decision making.  This CLIA certification is the natural next stage in becoming a lung cancer diagnostic leader.” said CEO, Sara Barrington.

ABOUT LUNGLIFE AI

LungLife AI is a cancer diagnostics company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled the molecular analysis of cancer biomarkers in blood.

LungLife AI is focused upon lung cancer diagnostic solutions recognizing the need to substantially improve patient outcomes. The company's testing methodology is designed to deliver actionable information to clinicians via a minimally invasive blood draw. Our tests span all stages of lung cancer, from aid in diagnosis for patients with suspicious lung nodules as well as treatment stratification and monitoring in late-stage lung cancer.

The CLIA regulations include federal standards applicable to all US facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CMS regulates this testing in the United States through the CLIA. The Centers for Disease Control and Prevention (CDC), in partnership with CMS and FDA, supports the CLIA program and clinical laboratory quality.

New name, new address. Cynvenio is now LungLife AI.

LungLife AI (Cynvenio) Names James McCullough as Board Member

WESTLAKE VILLAGE, CA – March 18, 2019 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that James McCullough has been appointed as Board member.

Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His focus is on equity and debt capital formation, strategic development and partnerships. James is currently the CEO of Renalytix AI, PLC, an AIM listed company (AIM: RENX), which develops Artificial Intelligence enabled In-Vitro Diagnostics for kidney disease.  James was most recently chief executive officer of Exosome Diagnostics, a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer, sold to Bio-Techne (NASDAQ: TECH).  James is also a managing partner of Renwick Capital, LLC (“Renwick”), a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution and a co-founder of PAIGE.AI, a computational pathology spin-out from the Memorial Sloan Kettering Cancer Center.

 “The Board is pleased to welcome James, and we strongly believe that his experience in both the private and public funding markets will assist LungLife AI into its next stage of development,” said Simon Raab, Chairman of LungLife AI’s Board of Directors. “The company’s Artificial Intelligence (AI) enabled diagnostic solutions are poised to transform liquid biopsy-based technologies, and James’ experience in this area will be invaluable.”

About LungLife AI, Inc.

LungLife AI is focused on the development of cancer diagnostic solutions, particularly in lung disease, recognizing the need to substantially improve patient outcomes. The company’s tests span all stages of cancer and are designed to deliver actionable information to clinicians via minimally invasive blood draw. LungLife AI is based in Thousand Oaks, California. For more information, please visit https://www.lunglifeAI.com/.

LiquidBiopsy® is a registered trademark of LungLife AI, Inc.

LungLife AI (Cynvenio) Names Sara Barrington as Chief Executive Officer

WESTLAKE VILLAGE, CA – January 2, 2019 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that its Board of Directors has named Sara Barrington as Chief Executive Officer and Board member.

Ms. Barrington has more than 20 years of executive leadership experience with focus in biotech. Before joining LungLife AI, she served as part of the Executive Team at Bruin Biometrics, an LA-based medical device company and prior to that at Exosome Diagnostics, a venture-backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer. Previously, she served as CFO for Creative Technology Group, Inc and AusAm Biotechnologies developing novel early stage kidney disease diagnostics.

“The Board is pleased to welcome Sara, and we strongly believe that she is the right leader to take LungLife AI into its next stage of development,” said Simon Raab, Executive Chairman of LungLife AI’s Board of Directors. “The company’s diagnostic solutions are poised to transform the diagnosis and management of lung cancer, and Sara’s experience in both strategy and strategic execution for emerging life science companies make her the right candidate to successfully lead LungLife AI to market.”

 “LungLife AI has been a pioneer in the development of liquid biopsy testing technology and molecular analysis,” commented Sara Barrington. “I look forward to working with the talented LungLife AI team to build upon the company’s progress and to bring these important solutions to physicians and cancer patients worldwide.”

About LungLife AI, Inc.

LungLife AI is focused on the development of cancer diagnostic solutions, particularly in lung disease, recognizing the need to substantially improve patient outcomes. The company’s tests span all stages of cancer and are designed to deliver actionable information to clinicians via minimally invasive blood draw. LungLife AI is based in Thousand Oaks, California. For more information, please visit https://www.lunglifeAI.com/.

LiquidBiopsy® is a registered trademark of LungLife AI, Inc.